Cutaneous Leishmaniasis Reinfection: Skin Disease and Leishmaniasis Research Center, Isfahan, Iran

Document Type : Original Article (s)

Authors

1 Professor, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan AND Skin and Stem cell Research Center, Tehran University of Medical Sciences, Tehran, Iran

2 Associate Professor, Skin and Stem cell Research Center, Tehran University of Medical Sciences, Tehran, Iran

3 Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

4 PhD Student, Department of Parasitology, School of Medicine, Kerman University of Medical Sciences, Kerman AND Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Cutaneous leishmaniasis is a self-limited disease that does not cause a major problem in terms of death and disability compared to other diseases. However, permanent disfiguring scar, long-term period of wound healing, secondary infection, drug side effects, treatment duration and secondary effects caused by the drugs increase the impact of the burden of this disease. This study was designed to investigate the status of cutaneous leishmaniasis reinfection in patients referred to Skin Disease and Leishmaniasis Research Center (SDLRC), Isfahan, Iran.Methods: Demographic information such as age, sex, number and place of lesion, migration to endemic areas, nationality, and occupation of the patients with cutaneous leishmaniasis referred to Skin Disease and Leishmaniasis Research Center parasitology laboratory in the years of 2012 and 2013 was collected.Findings: Of 1087 patients diagnosed as having cutaneous leishmaniasis, 75 patients (6.8%) had reinfection. Mean age of these patients was 34.73 ± 20.91 years (ranging 1-75). Women (41, 54.7%) were affected more than the men (34, 45.3%) with no statistically significant difference.Conclusion: Some patients with the history of cutaneous leishmaniasis may suffer reinfection after several years of recovery. Less than 10% of patients had this problem in the our study population. Several factors such as genotype or strain variations and immune deficiency due to chronic backgrounds may be involved in the process of reinfection. Further researches are warranted to explore the underlying pathophysiology.

Keywords

References

  1. Yan YL, Han F, Tan WM, Wu CP, Qin X. Association between the MDM2 T309G polymorphism and leukemia risk: a meta-analysis. Asian Pac J Cancer Prev 2014; 15(16): 6767-72.
  2. Kochethu G, Delgado J, Pepper C, Starczynski J, Hooper L, Krishnan S, et al. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia. Leuk Res 2006; 30(9): 1113-8.
  3. van den Broek EC, Kater AP, van de Schans SA, Karim-Kos HE, Janssen-Heijnen ML, Peters WG, et al. Chronic lymphocytic leukaemia in the Netherlands: trends in incidence, treatment and survival, 1989-2008. Eur J Cancer 2012; 48(6): 889-95.
  4. Liu YC, Hsiao HH, Yang WC, Liu TC, Chang CS, Yang MY, et al. MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib. Mol Carcinog 2014; 53(12): 951-9.
  5. Mandal RK, Yadav SS, Panda AK. No evidence of correlation between p53 codon 72 G > C gene polymorphism and cancer risk in Indian population: a meta-analysis. Tumour Biol 2014; 35(9): 8607-13.
  6. Xiong X, Wang M, Wang L, Liu J, Zhao X, Tian Z, et al. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res 2009; 33(11): 1454-8.
  7. Dong HJ, Fang C, Wang L, Fan L, Xu J, Wu JZ, et al. TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia. Med Oncol 2014; 31(4): 908.
  8. Majid A, Richards T, Dusanjh P, Kennedy DB, Miall F, Gesk S, et al. TP53 codon 72 polymorphism in patients with chronic lymphocytic leukaemia: identification of a subgroup with mutated IGHV genes and poor clinical outcome. Br J Haematol 2011; 153(4): 533-5.
  9. Wang C, Wang X. The role of TP53 network in the pathogenesis of chronic lymphocytic leukemia. Int J Clin Exp Pathol 2013; 6(7): 1223-9.
  10. Barnabas N, Shurafa M, Van Dyke DL, Wolman SR, Clark D, Worsham MJ. Significance of p53 mutations in patients with chronic lymphocytic leukemia: a sequential study of 30 patients. Cancer 2001; 91(2): 285-93.
  11. Hu Y, McDermott MP, Ahrendt SA. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res 2005; 11(7): 2502-9.
  12. Bloehdorn J, Langer Ch, Dohner H, Zenz T, Stilgenbauer S. P53 and microRNAs in chronic lymphocytic leukemia. Journal of Nucleic Acids Investigation 2010; 2: e8.
  13. Lahiri O, Harris S, Packham G, Howell M. p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia. Cancer Genet Cytogenet 2007; 179(1): 36-44.
  14. Chang FH, Tzeng DS, Lee TM, Chen TC, Hsu LS, Lung FW. Mutations in the p53 tumor suppressor gene in colorectal cancer in Taiwan. Kaohsiung J Med Sci 2003; 19(4): 151-8.
  15. Santos AM, Sousa H, Portela C, Pereira D, Pinto D, Catarino R, et al. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Biochem Biophys Res Commun 2006; 340(1): 256-62.
  16. Cao Z, Song JH, Park YK, Maeng EJ, Nam SW, Lee JY, et al. The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients. Neoplasma 2009; 56(2): 114-8.
  17. Zhang J, Zhuo WL, Zheng Y, Zhang YS. Polymorphisms of TP53 codon 72 with prostate carcinoma risk: a meta-analysis. Med Oncol 2010; 27(2): 540-6.
  18. Aoki MN, da Silva do Amaral Herrera AC, Amarante MK, do Val Carneiro JL, Fungaro MH, Watanabe MA. CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development. Int J Mol Med 2009; 23(3): 429-35.
  19. Mahasneh AA, Abdel-Hafiz SS. Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma. Saudi Med J 2004; 25(11): 1568-73.
  20. Fan R, Wu MT, Miller D, Wain JC, Kelsey KT, Wiencke JK, et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000; 9(10): 1037-42.
  21. Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, Nakazato H, et al. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci 2003; 10(4): 430-5.
  22. Dastjerdi MN. TP53 codon 72 polymorphism and P53 protein expression in colorectal cancer specimens in Isfahan. Acta Med Iran 2011; 49(2): 71-7.
  23. Nikbakht Dastjerdi M, Mirmohammad Sadeghi H. TP53 codon 72 heterozygosity may promote microsatellite instability in sporadic colorectal cancer. Cell J Yakhteh 2010; 12(1): 25-32.
  24. Nikbahkt Dastjerdi M, Salehi M, Mohajeri MR, Morsali F, Mirmohammad Sadeghi H, Esfandiary E. Evidence for an association of TP53 codon 72 polymorphism with sporadic colorectal cancer risk in Isfahan. J Res Med Sci 2008; 13(6): 317-23.
  25. Nikbakht Dastjerdi M, Hasanzadeh M, Talebi A, Akbari M. Investigation of P53 codon 72 polymorphism in patients with nonmelanoma skin cancers in Isfahan. J Isfahan Med Sch 2011; 29(141): 679-84. [In Persian].
  26. Bergamaschi G, Merante S, Orlandi E, Galli A, Bernasconi P, Cazzola M. TP53 codon 72 polymorphism in patients with chronic myeloid leukemia. Haematologica 2004; 89(7): 868-9.
  27. Hamu CS, Oliveira MVP, Silva AMTC, Cruz AD. Codon 72 polymorphism of the TP53 gene in patients suspected to have CML. Rev Bras Hematol Hemoter 2007; 29(4): 346-50.
  28. Nikbakht Dastjerdi M, Eslami Farsani B, Abutorabi R, Salehi R, Sanei MH. Analysis of TP53 codon 72 gene polymorphism in patients with endometriosis in Isfahan. J Isfahan Med Sch 2011; 29(157): 1327-34. [In Persian].
  29. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered 1994; 44(5): 266-70.
  30. Lu XM, Zhang YM, Lin RY, Liang XH, Zhang YL, Wang X, et al. p53 polymorphism in human papillomavirus-associated Kazakh's esophageal cancer in Xinjiang, China. World J Gastroenterol 2004; 10(19): 2775-8.
  31. Nikbakht Dastjerdi M. Investigation of p53 codon 72 polymorphism in patients with acute myeloid leukemia in Iran. Sci J Iran Blood Transfus Organ 2015; 12(1): 13-23.
Journal of Isfahan Medical School
Volume 33, Issue 341 - Serial Number 341
May and June 2015
Pages 1029-1036

Files

History

  • Receive Date: 23 February 2015
  • Revise Date: 02 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics